Low-Dose Naltrexone for Severe Fibromyalgia Syndrome: A Report of a Case With Two-Year Follow-Up
Low-Dose Naltrexone for Severe Fibromyalgia Syndrome: A Report of a Case With Two-Year Follow-Up Ulrich Moser | Published: May 10, 2025 https://www.cureus.com/articles/366372-low-dose-naltrexone-for-severe-fibromyalgia-syndrome-a-report-of-a-case-with-two-year-follow-up#!/ Abstract Fibromyalgia syndrome (FMS) is characterized by diffuse musculoskeletal pain associated with daytime fatigue, sleep disturbance, cognitive deficits, and often further somatic symptoms. While some patients with FMS respond to standard treatment with […]
Pseudo-endocrine Disorders: Recognition, Management, and Action
Pseudo-endocrine Disorders: Recognition, Management, and Action Michael T McDermott Journal of the Endocrine Society 17 December 2024 Abstract “Pseudo-endocrine disorders” refer to proposed conditions that have never been scientifically proven to exist but, due to widespread misinformation available on the internet and other media, are relatively commonly diagnosed and treated with equally unproven and sometimes […]
Beyond Antivirals: Alternative Therapies for Long COVID
Beyond Antivirals: Alternative Therapies for Long COVID Achilleas Livieratos, Charalambos Gogos, Karolina Akinosoglou 19 November 2024 Viruses Abstract Long COVID or Post-Acute Sequelae of SARS-CoV-2 infection (PASC) is a condition characterized by numerous lingering symptoms that persist for weeks to months following the viral illness. While treatment for PASC is still evolving, several therapeutic approaches […]
Diabetic Peripheral Neuropathy: Emerging Treatments of Neuropathic Pain and Novel Diagnostic Methods
Diabetic Peripheral Neuropathy: Emerging Treatments of Neuropathic Pain and Novel Diagnostic Methods Journal of Diabetes Science and Technology 16 September 2024 Johan Røikjer et al. Abstract Background: Diabetic peripheral neuropathy (DPN) is a prevalent and debilitating complication of diabetes, often leading to severe neuropathic pain. Although other diabetes-related complications have witnessed a surge of […]
Low-Dose Naltrexone Use in Biopsy-Proven Lichen Planus of the Nails
JAMA Dermatology, JAMA Network October 30, 2024 Low-Dose Naltrexone Use in Biopsy-Proven Lichen Planus of the Nails Eric R. Bray, MD PhD; Brian W. Morrison, MD https://jamanetwork.com/journals/jamadermatology/article-abstract/2825430 Key Points Question: Is low-dose naltrexone effective in treating nail lichen planus? Findings: In this single tertiary referral center case series of 7 patients with biopsy-proven nail lichen […]
A Utilization Review of Patients That Respond to Low-Dose Naltrexone (LDN) for Chronic Pain at a Single Institution
Journal of Pain and Palliative Care Pharmacotherapy 2024 Jun 5:1-8 A Utilization Review of Patients That Respond to Low-Dose Naltrexone (LDN) for Chronic Pain at a Single Institution Joshua Pogue, Diane Johnson & Andrew Burch Abstract Studies have demonstrated the benefits of LDN for various pain indications. This review describes the utilization of and response […]
Efficacy and safety of low-dose naltrexone for the management of fibromyalgia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis
The Korean Journal of Pain 2024 Oct 1;37(4):367-378 Akhil Deepak Vatvani, Pratik Patel, Timotius Ivan Hariyanto & Theo Audi Yanto Abstract Background: Fibromyalgia is characterized by the presence of chronic widespread pain that may impair patient’s quality of life. Currently, the use of naltrexone as a therapeutic agent for fibromyalgia is not supported by enough […]
Potential pathophysiological role of the ion channel TRPM3 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the therapeutic effect of low-dose naltrexone
Journal of Translational Medicine 2024 Jul 5;22(1):630. Matthias Löhn & Klaus Josef Wirth Abstract Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating disease with a broad overlap of symptomatology with Post-COVID Syndrome (PCS). Despite the severity of symptoms and various neurological, cardiovascular, microvascular, and skeletal muscular findings, no biomarkers have been identified. The Transient receptor […]
Potential pathophysiological role of the ion channel TRPM3 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the therapeutic effect of low-dose naltrexone
Review Open access Published: 05 July 2024 Volume 22, article number 630, (2024) Matthias Löhn & Klaus Josef Wirth Abstract Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating disease with a broad overlap of symptomatology with Post-COVID Syndrome (PCS). Despite the severity of symptoms and various neurological, cardiovascular, microvascular, and skeletal muscular findings, no biomarkers have been […]
Unraveling the neuroprotective mechanisms of naltrexone against aluminum-induced neurotoxicity
Unraveling the neuroprotective mechanisms of naltrexone against aluminum-induced neurotoxicity Sonia Sanajou et al., 14 Jan 2024, Drug and Chemical Toxicology https://www.tandfonline.com/doi/abs/10.1080/01480545.2024.2303975 Abstract Aluminum (Al) is a known neurotoxic trace element linked to Alzheimer’s disease (AD). Naltrexone, an opioid antagonist, has shown promising effects in reducing neuroinflammation at lower doses than those prescribed for addiction. This study […]